Hexamidine

Summary

Hexamidine (CHEMBL25105) is an approved small-molecule antimicrobial agent (ATC R02AA18); indicated across 2 conditions including eye infectious disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R02AA18 (+4 more)
• Indications: 2 conditions
• Chemistry: 354.4 Da · C20H26N4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL25105
Name	Hexamidine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	65130
ChEBI	CHEBI:87184
ATC	R02AA18, R01AX07, S01AX08, D08AC04, S03AA05
Molecular formula	C20H26N4O2
Molecular weight	354.4
InChIKey	OQLKNTOKMBVBKV-UHFFFAOYSA-N

SMILES: C1=CC(=CC=C1C(=N)N)OCCCCCCOC2=CC=C(C=C2)C(=N)N

IUPAC name: 4-[6-(4-carbamimidoylphenoxy)hexoxy]benzenecarboximidamide

ChEBI definition: A polyether that is the bis(4-guanidinophenyl) ether of hexane-1,6-diol.

Pharmacological roles (ChEBI): antimicrobial agent, antiseptic drug.

Also known as: Hexamidina, Hexamidine, HEXAMIDINE

Parent form; salt/anhydrous children: CHEMBL561781, CHEMBL3216902

Patent coverage: 1,922 distinct patent families (5,666 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prothrombin, Suppressor of tumorigenicity 14 protein, Urokinase-type plasminogen activator, Protein arginine N-methyltransferase 1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
F2	6.65	Ki	224	nM	CHEMBL_ACT_750476
ST14	6.03	Ki	924	nM	CHEMBL_ACT_750474
PRMT1	5.23	IC50	5900	nM	CHEMBL_ACT_29123276

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
eye infectious disorder	4	MONDO:0043885	EFO:1001888

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).